Publications

Prostate gland is a walnut sized organ located between the bladder and the penis. Prostatespecific antigen (PSA) is a protein produced by normal, as well as malignant cells of theprostate gland. The PSA test measures the level of PSA in a man’s blood. This study wasaimed at investigating the assessment of prostate specific antigen (PSA) in prostratedisorders. Study was carried out on a total of 80 patients attending clinic and laboratoryinvestigations from Achunike Hospital and St. Cyprian Hospital referred to Queens medicallaboratories for prostate specific antigen assay. Subjects were divided into four groups (A, B,C and D) their ages between 40 to 80 years. Group A is the control group. This groupcomprises apparently healthy individuals who have no history of prostate disorder. Group Bconsists of subjects with Prostatitis. Group C and Group D are patients with Benign prostatehyperplasia and prostate cancer respectively. Blood samples were collected venous in a plainsterile tube, allowed to clot and serum sample separated for PSA assay using Enzyme linkedImmunosorbent assay technique. The result of this study showed no significant (p > 0.05)change in PSA levels in group B diagnosed with prostatitis with mean values (2.84 ± 1.27).However, there was significant increase (P < 0.05) in PSA levels in subjects with Benignprostate hyperplasia (BPH) (14.11 ± 4.88) .The result of PSA levels in prostate cancer patientsshowed marked increase in PSA levels (19.64 ± 5.22) compared with control and also aremarkably higher PSA values compared with B and C (p < 0.05). Therefore this research workhas shown that prostate specific antigen is elevated in both benign prostate hyperplasia andprostate cancer. It has also identified PSA as an important marker in differentiating prostatedisorders caused by BPH and prostate cancer from disorders caused by prostatitis.